Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer
STUDY DESIGN
Design:
randomised controlled trial (European Randomised Study of Screening for Prostate Cancer [ERSPC]). Current Controlled Trials ISRCTN49127736.
Allocation:
not concealed, at least in part.* In 3 countries, randomisation occurred before consent was obtained; in the other 4 countries, only consenting participants were randomised, but allocation concealment was unclear.
Blinding:
blinded (outcome adjudication committees).*
STUDY QUESTION
Setting:
7 European countries.
Participants:
162 243 men 55–69 years of age (mean age 61 y). Some countries also enrolled …
